Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00341328
Recruitment Status : Completed
First Posted : June 21, 2006
Last Update Posted : April 26, 2013
Information provided by (Responsible Party):
SK Sharma, All India Institute of Medical Sciences, New Delhi

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : October 2011
  Study Completion Date : March 2012